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Abstract Since 2013, a new drugs-of-abuse trend attempts
to bypass drug legislation by marketing isomers of sched-
uled synthetic cannabinoids (SCs), e.g., FUBIMINA (BIM-
2201) and THJ-2201. It is much more challenging to con-
firm a specific isomer’s intake and distinguish it from its
structural analog because the isomers and their major
metabolites usually have identical molecular weights and
display the same product ions. Here, we investigated iso-
mers FUBIMINA and THJ-2201 and propose strategies to
distinguish their consumption. THJ-2201 was scheduled in
the US, Japan, and Europe; however, FUBIMINA is easily
available on the Internet. We previously investigated THJ-
2201 metabolism in human hepatocytes, but human FUBI-
MINA metabolism is unknown. We aim to characterize
FUBIMINA metabolism in human hepatocytes, recommend
optimal metabolites to confirm its consumption, and propose
strategies to distinguish between intakes of FUBIMINA and
THJ-2201. FUBIMINA (10 lM) was incubated in human
hepatocytes for 3 h, and metabolites were characterized with
high-resolution mass spectrometry (HR-MS). We identified
35 metabolites generated by oxidative defluorination, further
carboxylation, hydroxylation, dihydrodiol formation, glu-
curonidation, and their combinations. We recommend 50-
OH-BIM-018 (M34), BIM-018 pentanoic acid (M33), and
BIM-018 pentanoic acid dihydrodiol (M7) as FUBIMINA
specific metabolites. THJ-2201 produced specific metabolite
markers 50-OH-THJ-018 (F26), THJ-018 pentanoic acid
(F25), and hydroxylated THJ-2201 (F13). Optimized chro-
matographic conditions to achieve different retention times
and careful selection of specific product ion spectra enabled
differentiation of isomeric metabolites, in this case FUBI-
MINA from THJ-2201. Our HR-MS approach should be
applicable for differentiating future isomeric SCs, which is
especially important when different isomers have different
legal status.
Keywords FUBIMINA  BIM-2201  THJ-2201 
Synthetic cannabinoid  Hepatocyte metabolism  Isomer
Introduction
Synthetic cannabinoids (SCs) were originally developed as
tools to study the endogenous endocannabinoid system [1,
2]. Many SCs are CB1 and CB2 receptors agonists, eliciting
greater cannabimimetic effects than D9-tetrahydro-
cannabinol [3, 4]. However, SCs marketed as drugs-of-
abuse since the 2000s are an important global public health
and safety issue [5]. SC drug abuse can produce significant
human toxicity including agitation, seizures, hypertension,
emesis, myocardial infarction, and even death [6–9]. For
these reasons, many SCs were scheduled across the globe,
and many more structural analogs emerged. However, little
is known about metabolism of these new SCs, which makes
it challenging to document their intake in clinical
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screenings, complicated by the fact that the parent SCs
rarely are found in urine, the most common analytical
matrix.
Compared to structural analogs, it is much more
challenging to confirm the intake of isomers of scheduled
SCs by mass spectrometry (MS) because the SCs and
their major metabolites display identical molecular ions
and often identical product ions on a mass spectrometer.
FUBIMINA (BIM-2201), BIM-018, AB-CHMINACA,
and 1-n-pentyl-3-benzoylindole are isomers of THJ-2201,
THJ-018, AB-CHMINACA 2H-indazole analog, and
1-benzoyl-3-n-pentylindole, respectively (Fig. 1) [10–12].
In many cases, the isomers endow different scheduling
status. For instance, THJ-2201 is scheduled in the US,
Japan, and some European countries; however, FUBI-
MINA, while being scheduled in Japan since August
2014, is currently available over the Internet in the US.
Therefore, it is essential to confirm which SC is con-
sumed for the purpose of legal prosecution. Previously,
DeRuiter et al. [12] described the differentiation of 1-n-
pentyl-3-benzoylindole and 1-benzoyl-3-n-pentylindole.
However, the methods are limited to the parent drugs
without considering metabolites. Because all previously
studied SCs are extensively metabolized, major metabo-
lites information is more important than parents for con-
firmation of intake.
FUBIMINA [(1-(5-fluoropentyl)-1H-benzo[d]imidazol-
2-yl)(naphthalen-1-yl)methanone] was first detected in
2013 by Uchiyama et al. [11] in herbal-type products
purchased on the Internet. FUBIMINA, a potent agonist for
the CB2 receptor (Ki = 23.45 nM) [3], and THJ-2201 are
fluoro derivatives of BIM-018 and THJ-018, respectively
(Fig. 1). FUBIMINA was detected in seized samples since
February 2014, according to the United States Army
Criminal Investigation Laboratory (unpublished data).
All SCs investigated so far were highly metabolized,
with rare detection of the parent SCs in urine, making
identification of urinary metabolites essential to document
SC intake in this matrix [13, 14]. However, for newly
emerging SCs, metabolism data are generally unavailable.
We previously determined THJ-2201 metabolism with
human hepatocytes and high resolution mass spectrometry
(HR-MS) [15]. Currently, the only available FUBIMINA
metabolism data were reported by Wiley et al. [3], who
focused on FUBIMINA affinity and potency, only men-
tioning detection of some metabolites. In rat urine,
hydroxylation, oxidative defluorination, and carboxylation
metabolites were observed. However, these helpful pre-
liminary data also have limitations. Metabolism was in rats,
rather than humans; metabolites were mentioned, but no
structures were characterized; the relative abundance of
metabolites was not provided; and no marker metabolites
were recommended for future identification of FUBIMINA
intake.
Since 2005, HR-MS has become more widely available
for characterizing new drug metabolism due to its many
advantages over traditional unit-resolution MS [16],
including metabolite identification and bioactivation
mechanism elucidation [17–19]. Accurate mass measure-
ment efficiently confirms metabolite parent ion and frag-
ment ion formulas and achieves metabolite identification
with improved productivity and quality. Traditional unit-
resolution MS requires multiple injections with different
acquisition methods by experienced staff [16]; data
Fig. 1 Structures of pairs of isomeric synthetic cannabinoids
Forensic Toxicol (2016) 34:256–267 257
123
analysis is time-consuming and less reliable due to the
uncertainty of fragment elemental composition.
Our aims were to characterize human FUBIMINA
metabolism with human hepatocytes, recommend appro-
priate metabolites for clinical screening, and propose
strategies to distinguish FUBIMINA from THJ-2201
intake. Human hepatocytes contain all required cofactors,
enzymes, and an intact membrane, producing ratios of
metabolites more closely matched to those in authentic
human urine than those produced from human liver
microsomes (HLM) [20–22]. Our approach using HLM to
determine parent compound half-life and properly design
human hepatocyte experiments, human hepatocyte incu-
bation to produce phase I and phase II metabolites followed
by HR-MS analysis, and sophisticated data analysis have
proved successful in predicting major human urine
metabolites for other SCs including AB-PINACA [23],
AB-FUBINACA [24], FDU-PB-22, and FUB-PB-22 [14].
The spectral data for major metabolites will be highly
useful for clinical scientists to incorporate into their urine
screening methods to identify FUBIMINA intake.
Materials and methods
Chemicals and reagents
FUBIMINA (purity 98.42 %) was verified and kindly
provided by the Drug Enforcement Administration,
Department of Justice, USA. THJ-2201 and NADPH were
purchased from Cayman Chemical (Ann Arbor, MI, USA).
Cryopreserved human hepatocytes (10-donor pool), GRO
CP and GRO KHB (Krebs-Henseleit Buffer) buffer for
hepatocytes, and HLM (50-donor pool) were acquired from
BioreclamationIVT (Baltimore, MD, USA). Acetonitrile
was purchased from Sigma-Aldrich (St. Louis, MO, USA).
LC–MS grade water and formic acid were purchased from
Fisher Scientific (Waltham, MA, USA).
Metabolic stability of FUBIMINA in human liver
microsomes
The HLM metabolic stability assays were performed in the
same manner as in our previous manuscripts [25, 26]. Final
concentration of FUBIMINA in HLM incubation system
was 1 lM. Samples were centrifuged at 15,000g (4 C,
5 min); supernatant was stored at -80 C until analysis.
When analyzing, the samples were thawed, vortexed, and
centrifuged again. Then, 10 lL supernatant was diluted in
990 lL mobile phase A/B (90: 10, v/v). Ten microliters
was injected to determine remaining FUBIMINA.
The high-performance liquid chromatography (HPLC)
system consisted of two LC-20ADxr pumps, a DGU-
20A3R degasser, a SIL-20ACxr autosampler, and a CTO-
20A column oven (Shimadzu, Columbia, MD, USA). The
Kinetex C18 column (100 mm 9 2.1 mm, 2.6 lm; Phe-
nomenex, Torrance, CA, USA) was fitted with a Krud-
Katcher Ultra HPLC in-line filter (0.5 lm 9 0.1 mm,
Phenomenex). Mobile phases were 0.1 % formic acid in
water (A) and 0.1 % formic acid in acetonitrile (B). The
gradient elution started at 10 % B for 0.5 min, ramped to
95 % B at 10 min, then held until 12.5 min before re-
equilibrating at 10 % B for 2.5 min. Total run time was
15 min with a flow rate of 0.3 mL/min. Column and
autosampler temperatures were 40 and 4 C, respectively.
Data acquisition was performed on 3200 QTRAP mass
spectrometer (Sciex, Redwood City, CA, USA) with
Analyst software (version 1.6) in positive electrospray
ionization (?ESI) mode. Ion source parameters were as
follows: source temperature 500 C; ion spray voltage,
4000 V; curtain gas, 30 psi; gas 1, 45 psi; gas 2, 70 psi.
Two ion transitions were monitored for FUBIMINA (m/z
361 ? 155; m/z 361 ? 177). Mass parameters were as
follows: declustering potential, 61 V; collision energy,
43 eV (m/z 361 ? 155) and 35 eV (m/z 361 ? 177).
FUBIMINA peak areas were plotted against time, and
in vitro microsomal half-life (T1/2) and intrinsic clearance
(CLint, micr) were calculated. Microsomal intrinsic clear-
ance was then scaled to whole-liver dimensions, yielding
intrinsic clearance (CLint). Human hepatic clearance (CLH)
and extraction ratio (ER) were predicated based on CLint
without considering plasma protein binding.
Metabolite identification in human hepatocytes
Hepatocyte incubation was carried out as previously
described [15, 25, 26]. Cryopreserved human hepatocytes
were washed twice with GRO CP medium and GRO KHB
buffer. Cell viability was evaluated with Trypan blue
(0.4 %, v/v) exclusion method, assuring greater than 80 %
viability. FUBIMINA was incubated at a final concentra-
tion of 10 lM with human hepatocytes (1 9 106 cells/mL)
in a 24-well plate (BD Biosciences, San Jose, CA, USA).
Final incubation volume was 500 lL and samples were
incubated at 37 C. Chemical stability of FUBIMINA in
the KHB buffer, and hepatocyte incubation without
FUBIMINA also were performed (37 C, 3 h) to determine
whether metabolites are dependent on hepatocytes
enzymes or are impurities from hepatocyte itself.
Diclofenac was incubated as a positive control to ensure
metabolic activity of the hepatocytes by monitoring for-
mation of 40-hydroxydiclofenac and acyl b-D-glucuronide
diclofenac. The reactions were quenched by adding 500 lL
ice-cold acetonitrile at 0 and 3 h incubation. Samples were
stored at -80 C until analysis. Before analysis, samples
were thawed, vortexed thoroughly, and 100 lL acetonitrile
258 Forensic Toxicol (2016) 34:256–267
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added to 100 lL samples. After vortexing and centrifuga-
tion at 15,000 g (4 C, 5 min), supernatant was transferred
to a new 10-mL plastic tube, evaporated to dryness under
nitrogen at 40 C, and reconstituted in 150 lL mobile
phase A/B (80:20, v/v). Fifteen microliters of the recon-
stituted solution was injected for metabolite identification.
The HPLC system consisted of two LC-20ADxr pumps,
a DGU-20A5R degasser, a SIL-20ACxr autosampler, and a
CTO-20 AC column oven (Shimadzu). Chromatographic
separation was achieved on an Ultra Biphenyl column
(100 9 2.1 mm, 3 lm; Restek, Bellefonte, PA, USA) with
a guard column containing the same packing material.
Gradient elution was performed with 0.1 % formic acid in
water (A) and 0.1 % formic acid in acetonitrile (B) at a
flow rate of 0.5 mL/min. Initial gradient conditions were
20 % B, held for 0.5 min; then increased to 95 % B over
10.5 min, held until 13.0 min; and returned to 20 % B at
13.1 min and held until 15.0 min. The column and
autosampler were maintained at 30 and 4 C, respectively.
Data were acquired on a 5600? TripleTOF MS (Sciex)
in ?ESI mode. MS data were acquired by information-
dependent acquisition (IDA) in combination with multiple
mass defect filters (MDF) and dynamic background sub-
traction (DBS). Ion source parameters were as follows:
curtain gas, 45 psi; gas 1, 60 psi; gas 2, 75 psi; source
temperature 650 C; ion spray voltage, 4000 V; declus-
tering potential, 80 V; entrance potential, 10 V. For IDA,
spectra exceeding 100 cps were selected for the metabo-
lism-dependent tandem mass spectrometry MS/MS scan,
isotopes within 1.5 Da were excluded, mass tolerance was
50 mDa, and collision energy was set to 35 ± 15 eV. The
MS was calibrated automatically every three injections.
MetabolitePilot (version 1.5, Sciex) characterized
metabolites with different peak-finding algorithms includ-
ing MDF, predicted biotransformation, generic liquid
chromatography (LC) peak finding, common product ion
and neutral loss; LC peak intensity threshold was 500 cps,
MS 200 cps, and MS/MS 50 cps. Special attention was
given to phase II metabolites that were susceptible to in-
source fragmentation.
To distinguish FUBIMINA from THJ-2201, THJ-2201
hepatocyte samples incubated in the same procedure were
analyzed with the same acquisition and processing methods.
Results and discussion
Metabolic stability evaluation in human liver
microsomes
After determining remaining FUBIMINA at different time
points, the in vitro T1/2 was calculated to be 4.9 ± 0.03 min,
and in vitro CLint, micr was 0.142 mL/min/mg, corresponding
to intrinsic clearance (CLint) of 134.1 mL/min/kg after
scaling to whole-liver dimensions [27]. Without considering
plasma protein binding and with a simplified Rowland’s
equation [21, 28], we calculated the predicted human CLH as
17.4 mL/min/kg and ER as 0.87.
Metabolic stability, expressed as in vitro T1/2 and CLint
defines a drug’s susceptibility to metabolism. These values
facilitate the prediction of in vivo hepatic clearance, in vivo
T1/2, and bioavailability [21, 29]. According to criteria pro-
posed by Lave et al. [30], short T1/2, large CLint, and high ER
demonstrate that FUBIMINA is a high clearance drug.
Fragmentation of FUBIMINA and THJ-2201
FUBIMINA ([M ? H]?, m/z 361.1730) eluted at 8.70 min
and displayed characteristic product ions at m/z 273.1041,
233.1099, 213.1036, 177.0467, 155.0499, 145.0408, and
127.0552 (Fig. 2a, c). Fragment m/z 273.1041 was gener-
ated via neutral loss of the fluoropentyl chain; m/z
233.1099 and 145.0408 represent the benzimidazole core
with and without the fluoropentyl chain. Neutral HF loss
from m/z 233.1099 yielded m/z 213.1036; m/z 177.0467 is
formed by fluorine rearrangement, and m/z 155.0499 and
127.0552 correspond to the naphthalene moiety with or
without the acyl group.
THJ-2201 eluted later at 9.21 min (Fig. 2b), and pro-
duced similar fragments (Fig. 2d), but with quite different
relative ion abundances, as for m/z 177.0467 and 155.0499.
Notably, the prominent fragment m/z 273.1041 in FUBI-
MINA was not observed in THJ-2201.
FUBIMINA metabolites in human hepatocytes
In the 3 h hepatocyte sample, 35 metabolites were detected
(Fig. 3; Table 1). No metabolites were observed following
FUBIMINA incubation in buffer for 3 h, indicating that
metabolite formation was enzyme-dependent. An overview
of the metabolic pathway is shown in Fig. 4. Metabolites
were labeled ‘‘M’’ in sequential eluting order. Table 1 lists
metabolites with pathway description, retention time, m/z,
mass error, formula, fragment ions, and peak areas. Based
on MS peak areas, primary metabolites were BIM-018
pentanoic acid (M33), 50-OH-BIM-018 glucuronide (M20),
and BIM-018 pentanoic acid dihydrodiol (M7). The top ten
major metabolites were elucidated as described below, with
product ion spectra shown in Fig. 5.
Oxidative defluorination and further oxidation plus
glucuronidation
For M34, precursor m/z 359.1767 and fragment m/z
231.1125 were 1.9963 Da (–F ? OH) less than the corre-
sponding ions of FUBIMINA (Fig. 6e), indicating fluorine
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replacement by a hydroxyl group. Other fragments m/z
213.1019, 155.0491, 145.0396, and 127.0542 were the
same as for FUBIMINA, indicating that the benzimidazole
and naphthalene moieties were unmodified. Therefore,
M34 was proposed as the oxidative defluorination
metabolite, i.e., 50-OH-BIM-018. Oxidative defluorination
also was the primary metabolic pathway of THJ-2201 [15].
M34 was easily glucuronidated to yield 50-OH-BIM-018
glucuronide (M20) (Fig. 5a), the second most abundant
FUBIMINA metabolite. M20 fragment m/z 359.1765 was
formed via neutral glucuronide loss (-176.0324 Da).
Other fragments, m/z 273.1026, 231.1127, 155.0485, and
145.0395, were the same as for M34.
The predominant M34 metabolic pathway was oxidation
to BIM-018 pentanoic acid (M33, Fig. 6g). M33 generated
fragments at m/z 273.1038, 245.0930, 201.1032, 155.0500,
145.0404, and 127.0549. Among them, m/z 273.1038,
155.0500, 145.0404, and 127.0549 also were present in
FUBIMINA, indicating naphthalene and benzimidazole
moieties were intact. The m/z 201.1032 was formed via
neutral CO2 loss (-43.9898 Da) from m/z 245.0930.
Therefore, M33 was tentatively assigned as BIM-018
pentanoic acid. Subsequent glucuronidation of M33 led to
M18/M19/M22 that shared similar product ion spectra, all
of them displaying neutral loss of glucuronide (Fig. 5d).
M18/M19/M22 appeared in a cluster probably because of
acyl glucuronide migration [31].
M34 also underwent benzimidazole hydroxylation and
glucuronidation to M14/M16. Their major fragment, m/z
375.1714 was generated via loss of glucuronide (Fig. 5c).
Fragments m/z 289.0979 and 161.0343 were 15.9947 Da
(?O) larger than corresponding M34 ions, suggesting
benzimidazole hydroxylation. Glucuronidation may also
occur on the benzimidazole hydroxyl group.
M34 also underwent dihydrodiol formation yielding
M10. For M10 (Fig. 5f), fragments m/z 307.1081 and
179.0446 were 34.0051 Da (?2O ? 2H) larger than M34
corresponding ions, indicating dihydrodiol formation on
benzimidazole. Dihydrodiol ions lost water easily within
the MS collision cell, generating ions at m/z 289.0957 and
161.0345. Similarly, M33 (BIM-018 pentanoic acid) pro-
duced a dihydrodiol metabolite (M7), the 3rd largest
metabolite. M7 shared fragments m/z 245.0914, 201.1023,
and 145.0395 with M33 (Fig. 6i); fragments m/z 307.1077
Fig. 2 Extracted ion
chromatograms of FUBIMINA
(m/z 361.0730, a) and THJ-2201
(m/z 361.0730, b), their product
ion spectra and proposed
fragmentation (FUBIMINA, c;
THJ-2201, d)
Fig. 3 Metabolic profile of FUBIMINA after 3 h incubation in
human hepatocytes
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Table 1 Identification of FUBIMINA metabolites after 3 h incubation with human hepatocytes. Fragment ions were expressed in nominal mass
because of space restraint







Formula Fragment ions Area Rank
Parent 8.72 361.1711 0.1 C23H21N2OF 273, 233, 213,
177, 155, 145,
127
2.48E ? 04 NA
M1 M34 ? dioxidation ? glucuronidation 3.47 567.1984 1.8 C29H30N2O10 391, 305, 247,
229, 171, 161
1.83E ? 04 29
M2 M33 ? oxidation 3.71 389.1505 2.3 C23H20N2O4 371, 289, 201,
171, 145
2.59E ? 04 27
M3 M34 ? dioxidation ? glucuronidation 3.92 567.1973 0.0 C29H30N2O10 391, 247, 171,
161
2.12E ? 04 28
M4 N-Dealkylation ? oxidation ? glucuronidation 4.09 465.1298 1.2 C24H20N2O8 289, 161, 155 1.22E ? 04 34
M5 Oxidation ? dihydrodiol 4.10 411.1720 1.4 C23H23N2O4F 393, 375, 289,
271, 189, 171,
145
4.27E ? 04 20
M6 M34 ? dihydrodiol 4.14 393.1825 4.0 C23H24N2O4 375, 289, 271,
189, 171, 145
4.20E ? 04 21




9.27E ? 05 3
M8 M34 ? oxidation ? glucuronidation 4.21 551.2030 1.2 C29H30N2O9 375, 289, 231,
171, 145
1.07E ? 05 11
M9 Dioxidation ? glucurnidation 4.23 569.1932 0.4 C29H29N2O9F 393, 289, 249,
171, 145
6.40E ? 04 17
M10 M34 ? dihydrodiol 4.28 393.1823 3.5 C23H24N2O4 307, 289, 265,
179, 161, 155
1.10E ? 05 9
M11 M34 ? dioxidation ? glucuronidation 4.36 567.1978 0.9 C29H30N2O10 391, 305, 231 1.40E ? 04 32
M12 M33 ? oxidation 4.40 389.1506 2.6 C23H20N2O4 289, 245, 201,
171, 145
9.65E ? 04 12
M13 Oxidation ? dihydrodiol 4.40 411.1711 -0.8 C23H23N2O4F 393, 307, 289,
161, 155
3.51E ? 04 24
M14 M34 ? oxidation ? glucuronidation 4.47 551.2033 1.5 C29H30N2O9 375, 289, 247,
161
1.52E ? 05 7
M15 M34 ? dioxidation ? glucuronidation 4.57 567.1973 0.0 C29H30N2O10 391, 305 1.75E ? 04 30
M16 M34 ? oxidation ? glucuronidation 4.78 551.2033 1.6 C29H30N2O9 375, 289, 247,
161, 155
2.37E ? 05 5
M17 Dioxidation ? glucuronidation 4.89 569.1935 0.9 C29H29N2O9F 393, 289, 249,
193, 161
3.58E ? 04 23
M18 M33 ? glucuronidation 5.20 549.1876 1.5 C29H28N2O9 531, 373, 355,
273, 201, 155
6.98E ? 04 14
M19 M33 ? glucuronidation 5.39 549.1876 1.6 C29H28N2O9 531, 373, 355,
273, 201, 155
6.59E ? 04 16
M20 M34 ? glucuronidation 5.43 535.2084 1.7 C29H30N2O8 359, 273, 231,
155, 145
4.53E ? 06 2
M21 Oxidation ? glucuronidation 5.45 553.1985 0.7 C29H29N2O8F 377, 273, 249,
155
1.26E ? 05 8
M22 M33 ? glucuronidation 5.51 549.1876 1.5 C29H28N2O9 531, 373, 355,
273, 245, 201,
155, 145
2.35E ? 05 6
M23 M33 ? oxidation 5.56 389.1500 1.1 C23H20N2O4 289, 261, 217,
161, 155
2.88E ? 04 25
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and 189.0544 were 34.0039 Da larger than corresponding
ions of M33, suggesting naphthalene dihydrodiol forma-
tion. Additionally, FUBIMINA itself underwent dihydro-
diol formation yielding M27 (Fig. 5g). It shared fragment
m/z 155.0496 with FUBIMINA; fragments m/z 307.1080
and 267.1161 were 34.0039 Da larger than m/z 273.1041
and 233.1099 of FUBIMINA, respectively, suggesting
dihydrodiol formation on the benzimidazole.
Fluoropentyl chain hydroxylation and further conjugation
Fluoropentyl chain hydroxylation led to M35. M35 shared
fragments m/z 273.1024, 155.0487, 145.0393, and
127.0543 with FUBIMINA. M35 fragment m/z 249.1038
was 15.9939 Da (?O) larger than m/z 233.1099 of
FUBIMINA, indicating fluoropentyl chain hydroxylation.
The exact position of hydroxylation cannot be determined
by MS. Sequential glucuronidation generated M21
(Fig. 5e).
N-Oxide and glucuronidation
Similar to THJ-2201 [15], an unusual pathway for SC, i.e.,
N-oxide glucuronidation was observed for FUBIMINA
generating M26 and M29. Their most intense fragment m/z
377.1673 was generated via glucuronide loss (Fig. 5b).
Both metabolites shared product ions m/z 233.1088,
177.0454, 155.0485, and 145.0396 with FUBIMINA,
suggesting naphthalene, benzimidazole, and fluoropentyl
chain were unmodified. However, fragments m/z 289.0979,
249.1029, and 161.0343 indicate benzimidazole oxidation.
Therefore, we propose M26/M29 as N-oxide glucuronides
rather than glucuronides of hydroxylated metabolites.
Generally, neutral H2O loss, instead of O, was observed
between fragments of hydroxylated metabolites, whereas it
is common for N-oxides to lose O or an OH radical [32,
33]. This unusual biotransformation dominated metabolism
of an antidepressant vortioxetine [32], and anticonvulsants
GI265080 and GW273293 [34]. FUBIMINA N-oxide itself
was not observed, probably because it was easily
glucuronidated.
THJ-2201 major metabolites under the same
condition
THJ-2201 underwent similar metabolism in human hepa-
tocytes as FUBIMINA, including oxidative defluorination,
further carboxylation or glucuronidation, hydroxylation on
the fluoropentyl chain, and dihydrodiol formation on
naphthalene. THJ-2201 primary metabolites were 50-OH-
THJ-018 (F26) and its glucuronide F18, THJ-018 pentanoic
acid (F25), and hydroxylated THJ-2201 (F13); their pro-
duct ion spectra and fragmentation are shown in Fig. 6f, h,
j. THJ-2201 metabolite names were taken from our pre-
vious manuscript characterizing its metabolic profile [15].
THJ-2201 and FUBIMINA marker metabolites are shown
in Fig. 6b, d; notably, there are two isomer pairs (M34 and
F26, M33 and F25).
Table 1 continued






Formula Fragment ions Area Rank
M24 M33 ? oxidation 5.66 389.1507 2.9 C23H20N2O4 289, 201, 171, 145 6.07E ? 04 19
M25 Dioxidation ? glucuronidation 5.67 569.1935 0.9 C29H29N2O9F 393, 305, 265, 177 6.28E ? 04 18
M26 N-Oxide ? glucuronidation 5.74 553.1992 2.1 C29H29N2O8F 377, 289, 249, 233, 177,
161
4.11E ? 05 4
M27 Dihydrodiol 5.81 395.1773 2.0 C23H23N2O3F 307, 289, 267, 161, 155 1.07E ? 05 10
M28 M33 ? oxidation 5.84 389.1505 2.3 C23H20N2O4 273, 217, 155, 145, 127 2.70E ? 04 26
M29 N-Oxide ? glucuronidation 5.86 553.1990 1.6 C29H29N2O8F 377, 289, 249, 207, 193,
177, 161, 145
6.82E ? 04 15
M30 M33 ? oxidation 5.93 389.1502 1.5 C23H20N2O4 289, 201, 171, 145 8.81E ? 04 13
M31 M34 ? oxidation 5.96 375.1712 2.4 C23H22N2O3 289, 231, 171, 145 1.24E ? 04 33
M32 Oxidation ? sulfation 6.04 457.1236 1.8 C23H21N2O5FS 377, 249, 193, 161, 155 1.52E ? 04 31
M33 Oxidative defluorination to
carboxylic acid
6.87 373.1558 3.0 C23H20N2O3 273, 245, 201, 155, 145,
127
5.62E ? 06 1
M34 Oxidative defluorination 6.92 359.1756 0.6 C23H22N2O2 273, 231, 155, 145, 127 3.87E ? 04 22
M35 Oxidation 7.01 377.1661 0.4 C23H21N2O2 273, 249, 231, 155, 145,
127
1.15E ? 04 35
NA not applicable
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Specific metabolites to distinguish FUBIMINA
intake from THJ-2201
Because FUBIMINA and THJ-2201 possess different
legal status in different countries, unequivocal confirma-
tion of which SC was taken is essential in forensic cases.
In clinical and forensic urine screening tests, urine sam-
ples are usually hydrolyzed by b-glucuronidase [13, 35],
and major phase I metabolites monitored. Additionally,
glucuronide conjugates may degrade spontaneously at
room temperature [36, 37]. Therefore, we only propose
phase I metabolites or aglycones of dominant phase II
metabolites as urinary marker metabolites. This proved
successful in documenting intake of AB-FUBINACA
Fig. 4 Tentative metabolic
pathways of FUBIMINA in
human hepatocytes
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[24], AB-PINACA [23], FDU-PB-22 and FUB-PB-22
[14].
Based on our results, the most appropriate marker
metabolites to document FUBIMINA intake (Fig. 6a, b) are
50-OH-BIM-018 (M34), which is derived from the intense
M20, BIM-018 pentanoic acid (M33), and BIM-018 pen-
tanoic acid dihydrodiol (M7). For THJ-2201 (Fig. 6c, d),
optimal marker metabolites include 50-OH-THJ-018 (F26),
THJ-018 pentanoic acid (F25), and hydroxylated THJ-2201
(F13). The isomers M34 and F26 as well as M33 and F25
elute at different retention times, i.e., 6.92 (M34) versus
7.57 min (F26) and 6.87 (M33) versus 7.49 min (F25)
(Fig. 6a, c), and are distinguishable by different product ion
spectra. A unique fragment, m/z 273.1030 was always a
major fragment in FUBIMINA and its metabolites, whereas
it was only a negligible ion in THJ-2201 and its metabolites.
For instance,m/z 273.1030 and 155.0491 were the dominant
M34 fragments (Fig. 6e) whereas m/z 213.1026 and
145.0400 were the top F26 fragments and m/z 273.1030 was
not observed at all (Fig. 6f). In M33, m/z 273.1038 was the
most intense fragment; but it is absent in F25. Additionally,
presence of both m/z 245.0930 and 201.1032 are charac-
teristic for M33, versus m/z 245.0930, 227.0817, and
217.0965 for F25 (Fig. 6g, h).
Urine is the most common routine matrix for drug
screening because of easy accessibility and high drug
concentration compared to blood or oral fluid. There are
limitations to extrapolating human hepatocyte data to
human urine. Extrahepatic metabolism [38], transporter
involvement [39], and metabolite enrichment in urine [40]
might change relative abundance of urinary metabolites,
and thus selection of marker metabolites. Therefore, it is
preferable to obtain FUBIMINA and THJ-2201 positive
urine case samples, and confirm whether recommended
hepatocyte marker metabolites match those present in
authentic urine after SC intake. Unfortunately, such sam-
ples are currently unavailable despite our efforts to obtain
them.
Fig. 5 FUBIMINA major metabolites, product ion spectra, proposed structures, and fragmentation patterns (M7 and M33 are shown in Fig. 6)
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Conclusions
In summary, we characterized FUBIMINA metabolism in
human hepatocytes with HR-MS. We recommend 50-OH-
BIM-018 (M34), BIM-018 pentanoic acid (M33), and
BIM-018 pentanoic acid dihydrodiol (M7) as the most
promising urinary marker metabolites for documenting
FUBIMINA intake. Their retention times and unique
product ion spectra facilitate differentiation of FUBI-
MINA from THJ-2201 for clinical and forensic scientists.
The data will enable linkage of potential adverse
toxicological events to FUBIMINA or THJ-2201, in order
that the public can be informed of their toxicity. These
data also empower manufacturers to focus their synthesis
efforts on optimal metabolites. We suggest workflow to
differentiate isomeric SCs as follows: incubate SC iso-
mers in human hepatocytes, analyze incubation samples
by HPLC-HR-MS, characterize unique major metabolites’
retention times and fragmentation profile, and confirm
with case urine samples. Our strategies are applicable for
distinguishing other SC isomers with different legal
status.
Fig. 6 Profiles of marker metabolites for FUBIMINA (a) and THJ-2201 (c); structures of three metabolite markers for FUBIMINA (b) and THJ-
2201 (d), and their product ion spectra and proposed fragmentation (e M34; f F26; g M33; h F25; i M7; j F13)
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